Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
FDMT | US
-0.30
-2.92%
Healthcare
Biotechnology
30/06/2024
04/10/2024
9.97
10.51
10.56
9.78
4D Molecular Therapeutics Inc. a clinical-stage biotherapeutics company develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology cardiology and pulmonology. The company has product candidates that are in clinical trials such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310 which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition the company has two product candidates that are in preclinical development stage such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
52.5%1 month
84.5%3 months
106.1%6 months
86.4%-
-
0.96
0.02
0.02
-3.55
1.71
-
-126.75M
518.14M
518.14M
-
-849.12K
-
-97.90
-24.06
21.52
18.97
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
3.82
Range1M
7.63
Range3M
19.15
Rel. volume
0.59
Price X volume
6.28M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Oculis Holding AG Ordinary shares | OCS | Biotechnology | 13.2 | 551.04M | 8.20% | n/a | 1.19% |
Pharming Group N.V. | PHAR | Biotechnology | 8.04 | 545.40M | -0.74% | n/a | 63.43% |
Revance Therapeutics Inc | RVNC | Biotechnology | 5.22 | 543.82M | 0.58% | n/a | -378.95% |
UroGen Pharma Ltd | URGN | Biotechnology | 12.7 | 534.85M | 0.95% | n/a | 326.69% |
Third Harmonic Bio Inc. | THRD | Biotechnology | 12.52 | 514.54M | -0.71% | n/a | 1.40% |
SIGA Technologies Inc | SIGA | Biotechnology | 6.98 | 498.16M | 0.87% | 5.95 | 0.97% |
CorMedix Inc | CRMD | Biotechnology | 8.9 | 497.15M | 7.62% | n/a | 1.29% |
Emergent BioSolutions Inc | EBS | Biotechnology | 9.35 | 494.68M | 1.74% | n/a | 226.97% |
KalVista Pharmaceuticals Inc | KALV | Biotechnology | 11.36 | 490.93M | -4.05% | n/a | 3.62% |
PureTech Health plc | PRTC | Biotechnology | 20.33 | 486.74M | 5.39% | n/a | 29.73% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.55 | 0.76 | Cheaper |
Ent. to Revenue | 1.71 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 0.96 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 106.06 | 74.67 | Riskier |
Debt to Equity | 0.02 | -1.82 | Expensive |
Debt to Assets | 0.02 | 0.26 | Cheaper |
Market Cap | 518.14M | 3.73B | Emerging |